Business Description
Medivir AB
NAICS : 325412
ISIN : SE0020181014
Share Class Description:
OSTO:MVIR: Ordinary SharesCompare
Compare
Traded in other countries / regions
MVIR.SwedenMVR0.Germany0GP7.UKMVRBF.USA IPO Date
1996-02-29Description
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.83 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.12 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -4.39 | |||||
| Beneish M-Score | -3.04 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -31.1 | |||||
| 3-Year EBITDA Growth Rate | -10.8 | |||||
| 3-Year EPS without NRI Growth Rate | -7.3 | |||||
| 3-Year FCF Growth Rate | 16.1 | |||||
| 3-Year Book Growth Rate | -19.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.68 | |||||
| 9-Day RSI | 57.52 | |||||
| 14-Day RSI | 53.74 | |||||
| 6-1 Month Momentum % | -4.61 | |||||
| 12-1 Month Momentum % | -31.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.84 | |||||
| Quick Ratio | 1.84 | |||||
| Cash Ratio | 1.75 | |||||
| Days Sales Outstanding | 273.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -42.5 | |||||
| Shareholder Yield % | -6.09 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1767.41 | |||||
| Net Margin % | -1686.21 | |||||
| FCF Margin % | -1431.57 | |||||
| ROE % | -67.06 | |||||
| ROA % | -49.8 | |||||
| ROIC % | -79.34 | |||||
| ROC (Joel Greenblatt) % | -1012.72 | |||||
| ROCE % | -63.88 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 34.58 | |||||
| PB Ratio | 2.27 | |||||
| Price-to-Tangible-Book | 7 | |||||
| EV-to-EBIT | -1.4 | |||||
| EV-to-Forward-EBIT | -1.37 | |||||
| EV-to-EBITDA | -1.43 | |||||
| EV-to-Forward-EBITDA | -1.37 | |||||
| EV-to-Revenue | 23.93 | |||||
| EV-to-Forward-Revenue | 28.86 | |||||
| EV-to-FCF | -1.48 | |||||
| Price-to-Median-PS-Value | 1.4 | |||||
| Price-to-Net-Current-Asset-Value | 9.26 | |||||
| Price-to-Net-Cash | 10.63 | |||||
| Earnings Yield (Greenblatt) % | -71.38 | |||||
| FCF Yield % | -30.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medivir AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 6.934 | ||
| EPS (TTM) (kr) | -1.1 | ||
| Beta | -0.11 | ||
| Volatility % | 34.25 | ||
| 14-Day RSI | 53.74 | ||
| 14-Day ATR (kr) | 0.153823 | ||
| 20-Day SMA (kr) | 2.794 | ||
| 12-1 Month Momentum % | -31.71 | ||
| 52-Week Range (kr) | 2.33 - 3.99 | ||
| Shares Outstanding (Mil) | 112.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medivir AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medivir AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medivir AB Frequently Asked Questions
What is Medivir AB(OSTO:MVIR)'s stock price today?
The current price of OSTO:MVIR is kr2.87. The 52 week high of OSTO:MVIR is kr3.99 and 52 week low is kr2.33.
When is next earnings date of Medivir AB(OSTO:MVIR)?
The next earnings date of Medivir AB(OSTO:MVIR) is 2025-02-14 Est..
Does Medivir AB(OSTO:MVIR) pay dividends? If so, how much?
Medivir AB(OSTO:MVIR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers